AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
May 19, 2021
29864_dirs_2021-05-19_0469153d-676a-4552-b7fe-27f6ce286195.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-05-17
Reporting Person: Sanna Bastiano (EVP, Cell & Genetic Therapies)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-17 | Common Stock | S | 65 | $215.95 | Disposed | 34155 | Direct |
| 2021-05-17 | Common Stock | S | 47 | $216.88 | Disposed | 34108 | Direct |
Footnotes
F1: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $215.95 (range $215.42 to $216.32).
F3: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $216.88 (range $216.44 to $217.21).